We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Abcam Launches Multiplex miRNA Profiling Assays
Product News

Abcam Launches Multiplex miRNA Profiling Assays

Abcam Launches Multiplex miRNA Profiling Assays
Product News

Abcam Launches Multiplex miRNA Profiling Assays


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Abcam Launches Multiplex miRNA Profiling Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abcam plc have announced the launch of a range of multiplex miRNA profiling assays for high-throughput validation of miRNA biomarkers, based on Abcam’s new Firefly™ particle technology. 

The new Multiplex Cellular miRNA Assay and Multiplex Circulating miRNA Assay allow researchers to rapidly and cost-effectively profile up to 68 miRNAs in each well of a 96-well plate, with readout on a standard flow cytometer. These assays offer an easier workflow for larger sample numbers compared to alternative methods such as qPCR, microarray and sequencing, which can be resource intensive or require challenging data analysis.

The Multiplex Circulating miRNA assay enables profiling of miRNAs from small volumes of crude biofluids including serum and plasma, with no need for RNA purification, while the Multiplex Cellular miRNA Assay is optimized to work with purified RNA. The Multiplex Circulating miRNA Assay is particularly suited for studies targeting low-abundance miRNAs or where the amount of each sample is limiting.

Customers can chose between fixed panels targeting specific disease areas or can customize their own panel. Abcam also offers a sample profiling service to enable researchers without in-house resources to obtain profiles with this technology. Analysis software provided by Abcam efficiently translates the raw data from the flow cytometer into a miRNA profile and does not require special bioinformatics expertise. 

Brian Taylor, Head of Kits and Assays, Abcam, said: “We’re excited about the opportunities that Abcam’s Firefly particle technology will bring to global researchers undertaking miRNA research. We recognized a consumer need to enhance the tools available for miRNA research, and our new innovative assays provide a combination of performance, multiplexing, throughput, cost and ease of use not available from existing technologies.”

The assays can be purchased from Abcam in US and Europe and will be available globally in the course of 2015.  

Advertisement